The role of systemic therapy for localised gastric cancer

Annals of Oncology

Volumn 17, Issue SUPPL. 10, 2006, Pages

  Starling, N ^a   Cunningham, D ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; MATUZUMAB; METHOTREXATE; MITOMYCIN C; OXALIPLATIN;

ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RELAPSE; CANCER SURGERY; CAUSE OF DEATH; CLINICAL TRIAL; DIGESTIVE SYSTEM PERFORATION; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; NEUTROPENIA; PRIORITY JOURNAL; STOMACH CANCER; SURVIVAL RATE; SYSTEMIC THERAPY; THROMBOEMBOLISM;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; FORECASTING; HUMANS; NEOADJUVANT THERAPY; STOMACH NEOPLASMS;

EID: 33749616338     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl248     Document Type: Article

References (56)

1. Parkin DM, Pisani P, Ferlay J. Global Cancer Statistics. CA Cancer J Clin 1999; 49 (1): 33-64.
2. Sue-Ling HM, Johnston D, Martin IG et al. Gastric Cancer: A Curable Disease in Britain. BMJ 1993; 307 (6904): 591-596.
3. Sasako M, Sano T, Katai H et al. Radical Surgery. Sugimura, T. and Sasako, M. Gastric Cancer. Oxford University Press; 1997. pp. 223-248.
4. Siewert JR, Bottcher K, Roder JD et al. Prognostic Relevance of Systematic Lymph Node Dissection in Gastric Carcinoma. German Gastric Carcinoma Study Group. Br J Surg 1993; 80 (8): 1015-1018.
5. Catalano V, Labianca R, Beretta GD et al. Gastric Cancer. Crit Rev Oncol Hematol. 2005; 54 (3): 209-241.
6. Lim L, Michael M, Mann GB, Leong, T. Adjuvant Therapy in Gastric Cancer. J Clin Oncol 2005; 23 (25): 6220-6232.
7. Hermans J, Bonenkamp JJ, Boon MC et al. Adjuvant Therapy After Curative Resection for Gastric Cancer: Meta-Analysis of Randomized Trials. J Clin Oncol 1993; 11 (8): 1441-1447.
8. Earle CC, Maroun JA. Adjuvant Chemotherapy After Curative Resection for Gastric Cancer in Non-Asian Patients: Revisiting a Meta-Analysis of Randomised Trials. Eur J Cancer 1999; 35 (7): 1059-1064.
9. Mari E, Floriani I, Tinazzi A et al. Efficacy of Adjuvant Chemotherapy After Curative Resection for Gastric Cancer: A Meta-Analysis of Published Randomised Trials. A Study of the GISCAD (Gruppo Italiano Per Lo Studio Del Carcinomi Dell'Apparato Digerente). Ann Oncol 2000; 11 (7): 837-843.
10. Janunger KG, Hafstrom L, Glimelius B. Chemotherapy in Gastric Cancer: A Review and Updated Meta-Analysis. Eur J Surg 2002; 168 (11): 597-608.
11. Ajani JA, Ota DM, Jessup JM et al. Resectable gastric carcinoma. an evaluation of preoperative and postoperative chemotherapy. Cancer 1991; 68 (7): 1501-1506.
12. Ajani JA, Mayer RJ, Ota DM et al. Preoperative and Postoperative Combination Chemotherapy for Potentially Resectable Gastric Carcinoma. J Natl Cancer Inst 1993; 85 (22): 1839-1144.
13. Crookes P, Leichman CG, Leichman L et al. Systemic Chemotherapy for Gastric Carcinoma Followed by Postoperative Intraperitoneal Therapy: A Final Report. Cancer 1997; 79 (9): 1767-1775.
14. Hartgrink HH, van de Velde CJ, Putter H et al. H. Neo-Adjuvant Chemotherapy for Operable Gastric Cancer: Long Term Results of the Dutch Randomised FAMTX Trial. Eur J Surg Oncol 2004; 30 (6): 643-649.
15. Songun I, Keizer HJ, Hermans J et al. Chemotherapy for Operable Gastric Cancer: Results of the Dutch Randomised FAMTX Trial. The Dutch Gastric Cancer Group (DGCG). Eur J Cancer 1999; 35 (4): 558-562.
16. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: Final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). Proc Am Soc Clin Oncol 23 (16S). 2005. Abstr. 4001.
17. Ross P, Nicolson M, Cunningham D et al. Prospective Randomized Trial Comparing Mitomycin, Cisplatin, and Protracted Venous-Infusion Fluorouracil (PVI 5-FU) With Epirubicin, Cisplatin, and PVI 5-FU in Advanced Esophagogastric Cancer. J Clin Oncol 2002; 20 (8): 1996-2004.
18. Waters JS, Norman A, Cunningham D et al. Long-Term Survival After Epirubicin, Cisplatin and Fluorouracil for Gastric Cancer: Results of a Randomized Trial. Br J Cancer 1999; 80 (1-2): 269-272.
19. Webb A, Cunningham D, Scarffe JH et al. Randomized Trial Comparing Epirubicin, Cisplatin, and Fluorouracil Versus Fluorouracil, Doxorubicin, and Methotrexate in Advanced Esophagogastric Cancer. J Clin Oncol 1997; 15 (1): 261-267.
20. Wagner AD, Grothe W, Behl S et al. Chemotherapy for Advanced-Gastric Cancer. Cochrane Database Syst Rev 2005; (2): CD004064.
21. Medical Research Council Oesophageal Cancer Working Party. Surgical Resection With or Without Preoperative Chemotherapy in Oesophageal Cancer: A Randomised Controlled Trial. Lancet 2002; 359 (9319): 1727-1733.
22. Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy After Surgery Compared With Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction. N Engl J Med 2001; 345 (10): 725-730.
23. Macdonald JS, Smalley S, Benedetti J et al. Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and gastroesophageal junction: Update of the results of Intergroup Study INT-0116 (SWOG 9008). Proc Am Soc Clin Oncol 2004; 23: Abstr 6.
24. Cunningham D, Rao S, Sterling N et al. Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial. Proc Am Soc Clin Oncol 24 (18S). 2006. Abstr. LBA4017.
25. Ajani JA, Baker J, Pisters PW et al. CPT-11 Plus Cisplatin in Patients With Advanced, Untreated Gastric or Gastroesophageal Junction Carcinoma: Results of a Phase II Study. Cancer 2002; 94 (3): 641-646.
26. Blanke CD, Haller DG, Benson AB et al. A Phase II Study of Irinotecan With 5-Fluorouracil and Leucovorin in Patients With Previously Untreated Gastric Adenocarcinoma. Ann Oncol 2001; 12 (11): 1575-1580.
27. Dank M, Zaluski J, Barone C et al. Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1st-line-advanced gastric cancer patients. Proc Am Soc Clin Oncol 23 (16S). 2005. Abstr. 4003.
28. Moiseyenko VM, Ajani JA, Tjulandin SA et al. Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). Proc Am Soc Clin Oncol 2005; 23 (16S): Abstr 4002.
29. Jonjic N, Kovac K, Krasevic M et al. Epidermal Growth Factor-Receptor Expression Correlates With Tumor Cell Proliferation and Prognosis in Gastric Cancer. Anticancer Res 1997; 17 (5B): 3883-3888.
30. Tokunaga A, Onda M, Okuda T et al. Clinical Significance of Epidermal Growth Factor (EGF), EGF Receptor, and C-ErbB-2 in Human Gastric Cancer. Cancer 1995; 75 (6 Suppl): 1418-1425.
31. Hirono Y, Tsugawa K, Fushida S et al. Amplification of Epidermal Growth Factor Receptor Gene and its Relationship to Survival in Human Gastric Cancer. Oncology 1995; 52 (3): 182-188.
32. Vanhoefer U, Tewes M, Rojo F et al. Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor. J Clin Oncol 2004; 22 (1): 175-184.
33. Tabernero J, Rojo F, Jimenez E et al. A phase I PK and serial tumor and skin pharmacodynamic (PD) study of weekly (q1w), every 2-week (q2w) or every 3-week (q3w) 1 -hour (h) infusion EMD72000, a humanized monoclonal antiepidermal growth factor receptor (EGFR) antibody, in patients (pt) with advanced tumors. Proc Am Soc Clin Oncol 2003; 22: Abstr 770.
34. Rao S, Starling N, Benson M et al. Phase I study of the humanized epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with ECX (epirubicin, cisplatin and capecitabine) as first line treatment for advanced oesophagogastric (OG) adenocarcinoma. Proc Am Soc Clin Oncol 2005; 23 (16S): Abstr 4028.
35. Tabernero, Macarulla T, Ramos FJ, Baselga J. Novel Targeted Therapies in the Treatment of Gastric and Esophageal Cancer. Ann Oncol 2005; 16 (11): 1740-1748.
36. Dragovich T, McCoy S, Urba SG et al. SWOG 0127: Phase II Trial of Erlotinib in GEJ and Gastric Adenocarcinomas. Proc Gastrointestinal Am Soc Clin Oncol Symposium 2005; Abstr. 5.
37. Maeda K, Chung YS, Ogawa Y et al. Prognostic Value of Vascular Endothelial Growth Factor Expression in Gastric Carcinoma. Cancer 1996; 77 (5): 858-863.
38. Takahashi Y, Cleary KR, Mai M et al. Significance of Vessel Count and Vascular Endothelial Growth Factor and its Receptor (KDR) in Intestinal-Type Gastric Cancer. Clin Cancer Res 1996; 2 (10): 1679-1684.
39. Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T. Correlation Between Expression of Vascular Endothelial Growth Factor and Tumor Vascularity, and Patient Outcome in Human Gastric Carcinoma. J Clin Oncol 1997; 15 (2): 826-832.
40. Shah MA, Ramanathan RK, Ilson D et al. Final results of a multicenter phase II study of Irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with metastatic gastric or gastroesophageal (GEJ) adenocarcinoma (NCl #6447). Proc Am Soc Clin Oncol 24 (18S). 2006. Abstr 4020.
41. Shah MA, Ilson D, Kelsen DP. Thromboembolic Events in Gastric Cancer: High incidence in Patients Receiving Irinotecan- and Bevacizumab-Based Therapy. J Clin Oncol 2005; 23 (11): 2574-2576.
42. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004; 25 (4): 581-611.
43. Folkman J, Hanahan D. Switch to the Angiogenic Phenotype During Tumorigenesis. Princess Takamatsu Symp 1991; 22: 339-347.
44. Karayiannakis AJ, Syrigos KN, Polychronidis A et al. Circulating VEGF Levels in the Serum of Gastric Cancer Patients: Correlation With Pathological Variables, Patient Survival, and Tumor Surgery. Ann Surg 2002; 236 (1): 37-42.
45. Hyodo I, Doi T, Endo H et al. Clinical Significance of Plasma Vascular Endothelial Growth Factor in Gastrointestinal Cancer. Eur J Cancer 1998; 34 (13): 2041-2045.
46. Juttner S, Wissmann C, Jons T et al. Vascular Endothelial Growth Factor-D and its Receptor VEGFR-3: Two Novel Independent Prognostic Markers in Gastric Adenocarcinoma. J Clin Oncol 2006; 24 (2): 228-240.
47. Cascinu S, Graziano F, Del Ferro E et al. Expression of P53 Protein and Resistance to Preoperative Chemotherapy in Locally Advanced Gastric Carcinoma. Cancer 1998; 83 (9): 1917-1922.
48. Fondevila C, Metges JP, Fuster J et al. P53 and VEGF Expression Are Independent Predictors at Tumour Recurrence and Survival Following Curative Resection of Gastric Cancer. Br J Cancer 2004; 90 (1): 206-215.
49. Lowe SW, Ruley HE, Jacks T, Housman DE. P53-Dependent Apoptosis Modulates the Cytotoxicity of Anticancer Agents. Cell 1993; 74 (6): 957-967.
50. Bartek J, Bartkova J, Vojtesek B et al. Aberrant Expression of the P53 Oncoprotein Is a Common Feature of a Wide Spectrum of Human Malignancies. Oncogene 1991; 6 (9): 1699-1703.
51. Levine AJ. P53, the Cellular Gatekeeper for Growth and Division. Cell 1997; 88 (3): 323-331.
52. Ott K, Vogelsang H, Mueller J et al. Chromosomal Instability Rather Than P53 Mutation is Associated With Response to Neoadjuvant Cisplatin-Based Chemotherapy in Gastric Carcinoma. Clin Cancer Res 2003; 9 (6): 2307-2315.
53. Bataille F, Rummele P, Dietmaier W et al. Alterations in P53 Predict Response to Preoperative High Dose Chemotherapy in Patients With Gastric Cancer. Mol Pathol 2003; 56 (5): 286-292.
54. Lenz HJ, Leichman CG, Danenberg KD et al. Thymidylate Synthase MRNA Level in Adenocarcinoma of the Stomach: A Predictor for Primary Tumor Response and Overall Survival. J Clin Oncol 1996; 14 (1): 176-182.
55. Metzger R, Leichman CG, Danenberg KD et al. ERCC1 MRNA Levels Complement Thymidylate Synthase MRNA Levels in Predicting Response and Survival for Gastric Cancer Patients Receiving Combination Cisplatin and Fluorouracil Chemotherapy. J Clin Oncol 1998; 16 (1): 309-316.
56. Chen CN, Lin JJ, Chen JJ et al. Gene Expression Profile Predicts Patient Survival of Gastric Cancer After Surgical Resection. J Clin Oncol 2005; 23 (29): 7286-7295.